Fink Lynn Karen MD PhD

Neurology•Dallas, TX

Neurooncology

Physician

Join to View Full Profile

3410 Worth Street, Sammons Cancer CenterSuite 820Dallas, TX 75246
Phone+1 214-820-8690
Fax+1 214-820-8691

Education & Training

University of Texas Southwestern Medical CenterResidency, Neurology, 1991 - 1994
Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1990 - 1991
Mayo Clinic College of MedicineClass of 1990

Certifications & Licensure

TX State Medical License 1992 - 2026
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Start of enrollment: 1994 Jul 01
Completed
Phase 3
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
COMPLETED
PHASE1, PHASE2
DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors Start of enrollment: 2014 Sep 11
Completed
Phase 1
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma Start of enrollment: 2024 Dec 01
Suspended
Phase 3
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Start of enrollment: 2015 Jan 04
Completed
Phase 3
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Start of enrollment: 2016 Jul 01
Active, not recruiting
Phase 3
A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy Start of enrollment: 2017 Dec 08
Completed
Phase 3
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Start of enrollment: 2018 Jan 16
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

192 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...
Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim
JAMA Oncology. 2023-01-01
30 citations
A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
Vinay K. Puduvalli, Jing Wu, Ying Yuan, Terri S. Armstrong, Elizabeth Vera
Neuro-Oncology. 2020-10-14
155 citations
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma.
Patrick Y. Wen, David A. Reardon, Terri S. Armstrong, Surasak Phuphanich, Robert Aiken
Clinical Cancer Research. 2019-10-01

Grant Support

Continuous Taxol And Radiation Therapy For Glioblastoma MultiformeNational Center For Research Resources1997